Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Brigatinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lungcancer (NSCLC) Published 10 June 2019 1 SMC2147 brigatinib 30mg, 90mg and 180mg film-coated tablets (Alunbrig®) Takeda UK Ltd 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows (...) : ADVICE: following a full submission assessed under the end-of-life and ultra-orphan medicine process brigatinib (Alunbrig®) is accepted for use within NHSScotland. Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lungcancer (NSCLC) previously treated with crizotinib. Brigatinib was associated with an objective response rate of 56% in a single-arm, open- label, phase II study in patients with ALK
Durvalumab (Imfinzi) - for the treatment of locally advanced, unresectable non-small cell lungcancer (NSCLC) Published 10 June 2019 1 SMC2156 durvalumab 50mg/mL concentrate for solution for infusion (Imfinzi®) AstraZeneca 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission (...) considered under the ultra-orphan and end of life process durvalumab (Imfinzi®) is accepted for use within NHSScotland. Indication under review: as monotherapy for the treatment of locally advanced, unresectable non-small cell lungcancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on =1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy. Durvalumab, compared with placebo, improved progression-free survival and overall
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lungcancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lungcancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment (...) with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater.This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-cell lungcancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1% or greater
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell LungCancer Using a Clinicogenomic Database. Data sets linking comprehensive genomic profiling (CGP) to clinical outcomes may accelerate precision medicine.To assess whether a database that combines EHR-derived clinical data with CGP can identify and extend associations in non-small cell lungcancer (NSCLC).Clinical data from EHRs were linked with CGP results for 28 998 patients (...) EHRs.Overall survival (OS), time receiving therapy, maximal therapy response (as documented by the treating physician in the EHR), and clinical benefit rate (fraction of patients with stable disease, partial response, or complete response) to therapy.Among 4064 patients with NSCLC (median age, 66.0 years; 51.9% female), 3183 (78.3%) had a history of smoking, 3153 (77.6%) had nonsquamous cancer, and 871 (21.4%) had an alteration in EGFR, ALK, or ROS1 (701 [17.2%] with EGFR, 128 [3.1%] with ALK, and 42 [1.0
Alectinib (non-small cell lungcancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Alectinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (neues Anwendungsgebiet) (Version 1.0; Status: 28 March 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . IQWiG Reports – Commission No. A17-67 Alectinib (non-small cell lungcancer) – Benefit assessment according to §35a Social Code Book V 1 (new therapeutic indication) Extract of dossier assessment A17-67 Version 1.0 Alectinib (non-small cell lungcancer) 28 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lungcancer) – Benefit assessment according to §35a
Alectinib (non-small-cell lungcancer) - Addendum to Commission A17-67 1 Translation of addendum A18-30 Alectinib (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-67 (Version 1.0; Status: 1 June 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 1 June 2018 1.0 Commission: A18-30 Version: Status: IQWiG Reports – Commission No. A18-30 (...) Alectinib (non-small cell lungcancer) – Addendum to Commission A17-67 1 Addendum A18-30 Version 1.0 Alectinib – Addendum to Commission A17-67 1 June 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lungcancer) – Addendum to Commission A17-67 Commissioning agency: Federal Joint Committee Commission awarded on: 8 May 2018 Internal Commission No.: A18-30 Address
Atezolizumab (non-small cell lungcancer) – Addendum to Commission A17-50 1 Translation of addendum A18-09 Atezolizumab (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-50 (Version 1.0; Status: 23 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 23 February 2018 1.0 Commission: A18-09 Version: Status: IQWiG Reports (...) – Commission No. A18-09 Atezolizumab (non-small cell lungcancer) – Addendum to Commission A17-50 1 Addendum A18-09 Version 1.0 Atezolizumab – Addendum to Commission A17-50 23 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Atezolizumab (non-small cell lungcancer) – Addendum to Commission A17-50 Commissioning agency: Federal Joint Committee Commission awarded on: 5 February 2018
Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lungcancer patients. Pulmonary complications are often seen during the postoperative period following lung resection for patients with lungcancer. Some situations such as intubation, a long stay in the intensive care unit, the high cost of antibiotics and mortality may be avoided with the prevention of postoperative pulmonary complications. Non-invasive positive pressure ventilation (NIPPV (...) ) is widely used in hospitals, and is thought to reduce the number of pulmonary complications and mortality after this type of surgery. Therefore, a systematic review is needed to critically assess the benefits and harms of NIPPV for patients undergoing lung resection. This is an update of a Cochrane review first published in 2015.To assess the effectiveness and safety of NIPPV for preventing complications in patients following pulmonary resection for lung cancer.We searched the Cochrane Central Register
Exercise training for advanced lungcancer. Patients with advanced lungcancer have a high symptom burden, which is often complicated by coexisting conditions. These issues, combined with the indirect effects of cancer treatment, can cumulatively lead patients to continued deconditioning and low exercise capacity. This is a concern as exercise capacity is considered a measure of whole body health, and is critical in a patient's ability to participate in life activities and tolerate difficult (...) treatments. There is evidence that exercise training improves exercise capacity and other outcomes, such as muscle force and health-related quality of life (HRQoL), in cancer survivors. However, the effectiveness of exercise training on these outcomes in people with advanced lungcancer is currently unclear.The primary aim of this review was to investigate the effects of exercise training on exercise capacity in adults with advanced lungcancer. Exercise capacity was defined as the six-minute walk
Crizotinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lungcancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization
Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for LungCancer Based on the Nationwide Readmissions Database Readmission after surgery is an established surrogate indicator of quality of care. We aimed to compare short-term readmission rates and patient outcomes between open, video-assisted thoracoscopic (VATS), and robotic lobectomies in the Nationwide Readmissions Database (NRD).Adults who underwent open, VATS, or robotic lobectomy for lungcancer from 2010 to 2014 (...) were evaluated. Propensity-matched analysis was used to assess differences in readmission characteristics, GDP-adjusted cost, and mortality.Of the 129,539 lobectomies for lungcancer, 74,493 (57.5%) were open, 48,185 (37.2%) VATS, and 6861 (5.3%) robotic. Open surgery was associated with significantly higher readmission rate (10.5 vs 9.3%, p < 0.001), mortality (2 vs 1.2%, p < 0.001), index hospitalization cost [$21,846 (16,158-31,034) vs $20,779 (15,619-27,920), p < 0.001], and length of stay [6
Persisting new nodules in incidence rounds of the NELSON CT lungcancer screening study The US guidelines recommend low-dose CT (LDCT) lungcancer screening for high-risk individuals. New solid nodules after baseline screening are common and have a high lungcancer probability. Currently, no evidence exists concerning the risk stratification of non-resolving new solid nodules at first LDCT screening after initial detection.In the Dutch-Belgian Randomized LungCancer Screening (NELSON) trial (...) nodules were resolving, leaving 356 (52%) participants with a non-resolving new solid nodule, of whom 25 (7%) were diagnosed with lungcancer. At first screening after initial detection, volume doubling time (VDT), volume, and VDT combined with a predefined ≥200 mm3 volume cut-off had high discrimination for lungcancer (VDT, area under the curve (AUC): 0.913; volume, AUC: 0.875; VDT and ≥200 mm3 combination, AUC: 0.939). Classifying a new solid nodule with either ≤590 days VDT or ≥200 mm3 volume
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell LungCancer: ECOG-ACRIN 2511 Study Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lungcancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC).Patients with ES-SCLC, stratified by sex and serum
Whole brain radiotherapy provides little benefit for lungcancer that has spread Whole brain radiotherapy provides little benefit for lungcancer that has spread Discover Portal Discover Portal Whole brain radiotherapy provides little benefit for lungcancer that has spread Published on 10 January 2017 doi: Radiotherapy to the whole brain makes little difference to people with the commonest type of lungcancer that has spread to the brain and cannot be operated on. This mainly UK-based trial (...) found no difference in overall survival and quality of life among people who had whole brain radiotherapy plus usual supportive care compared with people who received supportive care alone. This is the largest trial to assess the effect of this treatment in people with non-small cell lungcancer and multiple brain metastases (cancer deposits in the brain). Practice has been changing since early results of the trial were released. The final results reinforce the message that this treatment has little
Postoperative radiotherapy reduces survival after surgery to remove non-small cell lungcancer Postoperative radiotherapy reduces survival after surgery to remove non-small cell lungcancer Discover Portal Discover Portal Postoperative radiotherapy reduces survival after surgery to remove non-small cell lungcancer Published on 28 February 2017 doi: Postoperative radiotherapy increases the risk of death by 18% for patients with non-small cell lungcancer that has been removed by surgery. Just (...) recurrence rates. Most of the trials are from over 30 years ago, so there is the possibility that newer radiotherapy techniques may be less harmful. Nevertheless, this review provides the best evidence to date that postoperative radiotherapy may not be appropriate as a routine treatment for non-small cell lungcancer. Share your views on the research. Why was this study needed? Lungcancer is the second most common cancer in the UK with 37,453 new cases registered in 2014. The majority of lungcancers
Circulating high sensitivity C reactive protein concentrations and risk of lungcancer: nested case-control study within LungCancer Cohort Consortium. To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lungcancer overall, by smoking status (never, former, and current smokers), and histological sub-type.Nested case-control study.20 population based cohort studies in Asia, Europe, Australia (...) , and the United States.5299 patients with incident lungcancer, with individually incidence density matched controls.Circulating hsCRP concentrations in prediagnostic serum or plasma samples.Incident lungcancer diagnosis.A positive association between circulating hsCRP concentration and the risk of lungcancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P
A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lungcancer Stereotactic body radiation therapy is the preferred treatment modality for patients with inoperable early-stage non-small cell lungcancer. However, comparative outcomes between stereotactic body radiation therapy and surgery for high-risk patients remain controversial. The primary aim of the present meta-analysis was to assess overall survival in matched (...) and unmatched patient cohorts undergoing stereotactic body radiation therapy or surgery. Secondary end points included cancer-specific survival, disease-free survival, disease recurrence, and perioperative outcomes.A systematic review of relevant studies was performed through online databases using predefined criteria. The most updated studies were selected for meta-analysis according to unmatched and matched patient cohorts.Thirty-two studies were identified in the systematic review, and 23 were selected